Molecular Stratification and Novel Therapeutic Approaches for Meningioma

Summary
 Advances in the molecular characterization of meningioma have transformed our understanding of this historically heterogeneous tumor group. Copy number alterations, gene mutations, and epigenetic signatures now offer a more precise framework for stratifying risk and predicting clinical behavior beyond traditional histopathology. 
 

In parallel, emerging imaging modalities—including advanced PET/MRI techniques and theranostic approaches—are providing new opportunities to non‑invasively assess tumor biology, guide treatment decisions, and monitor response.
This session will synthesize current knowledge on the molecular landscape of meningioma, highlighting how specific genomic and chromosomal alterations inform prognosis and therapeutic selection. Novel imaging strategies and their clinical applications will be reviewed, emphasizing their role in refining diagnosis and surveillance. Finally, the session will examine contemporary management approaches, including surgery, radiation, and systemic therapies, and will explore targeted and biologically informed treatments now in development. Together, these perspectives underscore the growing potential for precision medicine to reshape the care of patients with meningioma.

Learning Objectives:

• Understand copy number and other molecular alterations that enable more precise stratification of meningioma.
• Understand novel imaging approaches for meningioma and discuss their clinical application.
• Review current therapeutic approaches for meningioma and discuss targeted approaches in development.

Co-Chairs:

• Nicolas Gonzalez-Castro, Mass General Brigham
• David Solomon, Stanford University School of Medicine
• Ramon Barajas, Jr, Oregon Health & Science University
• Mary Jane Lim-Fat, Sunnybrook Health Sciences Centre